Skip to Main Content

Over the next few weeks, several major pharmaceutical companies will face a fresh crop of shareholder proposals that would require them to take steps to widen access to their medicines, an issue that is drawing increasing attention from investors.

The proposals address such topics as making Covid-19 medical products more accessible, aligning lobbying with public policy goals for promoting greater affordability, and reining in anticompetitive practices. Another proposal would require feasibility studies for transferring technology and know-how that could be used by generic manufacturers to make needed products for low-income countries.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment